Nuvo Pharmaceuticals Inc MRVFF

Healthcare Drug Manufacturers - Specialty & Generic

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.

OTCQX:MRVFF - Post by User

Nuvo Pharmaceuticals Inc > Q1 highlights

<< Previous

Bullboard Posts

Next >>

Post by lscfaon May 11, 2020 10:20am

407 Views

Post# 31011531

Q1 highlights

Q1 2020 Financial Highlights

For the three months ended March 31, 2020, adjusted total revenue⁽¹⁾ was $18.9 million, an increase of 11% compared to $17.1 million for the three months ended March 31, 2019.
The Company's Commercial Business segment includes the promoted products – Blexten^® and Cambia^®. Revenue related to these products was $6.0 million, an increase of 94% compared to revenue of $3.1 million for the three months ended March 31, 2019. Canadian prescriptions of Blexten and Cambia increased by 54% and 30% respectively compared to the three months ended March 31, 2019.
For the three months ended March 31, 2020, adjusted EBITDA⁽¹⁾ was $8.0 million, an increase of 53% compared to $5.2 million for the three months ended March 31, 2019.
Principal loan repayments of $11.5 million (US$8.7 million) were made in the three months ended March 31, 2020.